Universal Biosensors, Inc.
ABN 51 121 559 993
1 Corporate Avenue
Rowville Victoria 3149
Australia
Telephone: +61 3 9213 9000
Facsimile: +61 3 9213 6490
Email: info@universalbiosensors.com
www.universalbiosensors.com
15 June 2010
Universal Biosensors, Inc. (ASX: UBI) announced today that LifeScan, Inc had provided information concerning its strategic intentions for Its OneTouch® Verio™ product developed with UBI.
This occurred during the Diabetes Care Franchise Review, which was part of the Johnson & Johnson Medical Devices and Diagnostics Business Review with analysts. The relevant presentations were given by the Worldwide Chairman of Johnson & Johnson's Medical Devices and Diagnostics Group, Mr Alex Gorsky and the Diabetes Care Franchise Company Group Chairman, Mr Michel Paul, and are available by cutting and pasting the following link into your search engine or browser and following the relevant link:
investor.jnj.com/webcasts-presentations.cfm
Enquiries:
Mark Morrisson +61 3 9213 9000
About Universal Biosensors
For additional information in relation to Universal Biosensors, refer to
http://www.universalbiosensors.com/announcements.html.
Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-ofcare use. These tests capitalize on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.
Universal Biosensors' first product, developed in conjunction with LifeScan, Inc, is a next generation test for diabetics to self - monitor blood glucose. The product was launched in The Netherlands in January 2010. The relationship with LifeScan, Inc dates from 2001. In 2009 the two companies entered into an updated Master Services and Supply Agreement under which Universal Biosensors agreed to be a non-exclusive manufacturer of blood glucose sensor strips. Universal Biosensors is currently developing other point-of-care blood tests from its technology platform, which it intends to partner in due course.
Under applicable United States securities laws all of the shares of our common stock are "restricted securities" as that term is defined in Rule 144 under the Securities Act of 1933, as amended (Securities Act). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.
| © Copyright 1996-2010 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |